IDEAYA is an oncology-focused biotechnology company committed to the discovery and development of transformative personalized medicines. We employ a translational platform based on cutting-edge technologies for discovery, validation and clinical development of biomarkers in parallel with novel therapeutics. Our biomarkers enable patient selection – identifying patients most likely to respond to a particular therapeutic, as well as target engagement – confirming that a therapeutic molecule is acting on its intended target. IDEAYA is applying its biomarker-enabled translational platform across several mechanistic approaches based on cancer biology, including targeted therapies that directly target tumor genomic susceptibilities, breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism. IDEAYA, headquartered in South San Francisco, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology, translational biology, small molecule drug discovery, and clinical development.
”IDEAYA was founded with the premise that attracting the industry's best scientists and focusing on areas of transformative research is a proven model for delivering game-changing medicines to patients. Our people are passionate and proven cancer biologists, translational biologists, drug discovery chemists and development professionals. As an organization, we believe that our entrepreneurial spirit and nimbleness, and commitment to foster innovation, teamwork and excellence is what sets us apart. Our greatest asset is our scientists and their passion to discover innovative new therapies for cancer patients.Yujiro S. HataIDEAYA Chief Executive Officer